Official Title
Study of the SARS-COV-2 (COVID-19) Serological Profile of an Army Training Hospital Staff
Brief Summary

Emerging in China in December 2019, Covid-19, whose pathogen is SARS-Cov-2, was declared a global pandemic in March 2020. The clinical presentation is highly variable, ranging from asymptomatic forms to acute respiratory distress and even death. Transmission occurs through droplets, with a R0 of approximately 3. Rapidly, population protection measures were put in place by governments, including the confinement of all persons whose functions were not considered essential and the closure of educational institutions. Health care institutions are places at risk of Covid-19 transmission and hospital staff are particularly exposed, either through direct contact with patients, contact with exposed persons or through the environment. In order to protect personnel, hygiene measures were immediately recalled and reinforced. This study is aimed at evaluating the incidence rate of anti-SARS-Cov2 seroconversion over 2 months among hospital staff, without any supposed anti-Covid treatment 19.

Completed
SARS-COV2

Diagnostic Test: Anti-SARS-CoV2 Serology

A blood sample is collected by venipuncture at Day 0, Day 30 and Day 60. The anti-SARS-CoV2 serological status is measured by automated microplate ELISA technique on the EVOLIS analyzer (Biorad®), using reagent kits from EUROIMMUN France.

Other: Questionnaire

Data concerning personal exposure factors are collected in a questionnaire:
Socio-demographic factors: sex, age
Professional factors: Employment (type, pace, reception, service, care practices), wearing of personal protective equipment (type of equipment, frequency of use) and type of hospital
Non-professional factors: Contact with infected individuals, carrying of professional equipment and compliance with barrier measures

Eligibility Criteria

Inclusion Criteria:

- Army Training Hospital staff

Exclusion Criteria:

- Individuals who have already been confirmed Covid-19 positive

- Individuals taking preventive anti-Covid-19 therapy or considering participating in
anti-Covid-19 therapy study

- Individuals on hydroxychloroquine

- Pregnant or breastfeeding women

- Non-permanent staff during the study period

- Individuals identified for a detachment outside the metropole during the study period

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 62 Years
Countries
France
Locations

Hôpital d'Instuction des Armées Sainte-Anne
Toulon, France

Hôpital d'Instruction des Armées Robert Picqué
Villenave-d'Ornon, France

Direction Centrale du Service de Santé des Armées
NCT Number